



17-27-06

Jpw

PTO/SB/21 (09-04)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM (to be used for all correspondence after initial filing)	Application Number	10/507,928-Conf. #6804
	Filing Date	March 19, 2003
	First Named Inventor	Ralph P. Braun
	Art Unit	1633
	Examiner Name	Not Yet Assigned
Total Number of Pages in This Submission	Attorney Docket Number	HO-P03173US0

ENCLOSURES (Check all that apply)		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Reply to Missing Parts/Incomplete Application <input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____ <input type="checkbox"/> Landscape Table on CD	<input type="checkbox"/> After Allowance Communication to TC <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): Return Receipt Postcard 22 References
<div>Remarks</div>		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT			
Firm Name	FULBRIGHT & JAWORSKI L.L.P.		
Signature			
Printed name	Melissa W. Acosta, Ph.D.		
Date	July 26, 2006	Reg. No.	45,872



Docket No.: HO-P03173US0
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Ralph P. Braun et al.

Application No.: 10/507,928

Confirmation No.: 6804

Filed: March 19, 2003

Art Unit: 1633

For: IMIDAZOQUINOLINEAMINES A
ADJUVANTS IN HIV DNA VACCINATION

Examiner: Not Yet Assigned

INFORMATION DISCLOSURE STATEMENT (IDS)

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is filed before the mailing date of a first Office Action on the merits as far as is known to the undersigned (37 CFR 1.97(b)(3)).

Applicant has not submitted copies of each cited U.S. patent and U.S. patent application as required by 37 CFR 1.98(a)(2)(i), amended October 2004, as the U.S. Patent and Trademark Office has waived this requirement for all U.S. patent applications. Applicant submits herewith copies of foreign and non-patents in accordance with 37 CFR 1.98(a)(2).

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure statement shall not be construed to be an


admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 06-2375, under Order No. HO-P03173US0.

Dated: July 26, 2006

Respectfully submitted,

By 

Melissa W. Acosta, Ph.D.

Registration No.: 45,872

FULBRIGHT & JAWORSKI L.L.P.

Fulbright Tower


1301 McKinney, Suite 5100

Houston, Texas 77010-3095

(713) 651-5151

(713) 651-5246 (Fax)

Agent for Applicant



PTO/SB/08A (10-01)

Approved for use through 10/31/2002.OMB 0651-0031

U. S. Patent and Trademark Office: U. S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1 of 2

Complete if Known

Application Number	10/507,928
Filing Date	March 19, 2003
First Named Inventor	Ralph P. Braun
Art Unit	1633
Examiner Name	Not Yet Assigned
Attorney Docket Number	HO-P03173US0

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	A1	US-4,689,338	08-25-1987	Gerster	
	A2	US-4,929,624	05-29-1990	Gerster et al.	
	A3	US-5,238,944	08-24-1993	Wick et al.	
	A4	US-5,266,575	11-30-1993	Gerster et al.	
	A5	US-5,268,376	12-07-1993	Gester	
	A6	US-5,346,905	09-13-1994	Gerster	
	A7	US-5,352,784	10-04-1994	Nikolaides et al.	
	A8	US-5,389,640	02-14-1995	Gerster et al.	
	A9	US-5,395,937	03-07-1995	Nikolaides et al.	
	A10	US-5,482,936	01-09-1996	Lindstrom	
	A11	US-5,494,916	02-27-1996	Lindstrom et al.	
	A12	US-5,525,612	06-11-1996	Gerster	
	A13	US-6,083,505	07-04-2000	Miller et al.	
	A14	US-6,245,776	06-12-2001	Skwierczynski et al.	
	A15	US-20010006950-A1	07-05-2001	Punnonen et al.	
	A16	US-6,323,200	11-27-2001	Gerster et al.	
	A17	US-6,331,539	12-18-2001	Crooks et al.	
	A18	US-6,558,951	05-06-2003	Tomai et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
	B1	WO-98/46263	10-22-1998	Lu		
	B2	WO-99/29693	06-17-1999	Lindstrom et al.		
	B3	WO-01/47955	07-05-2001	Hanke et al.		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant

¹ Applicant's unique citation designation number (optional). ² See attached Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the application number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	C1	Bryant et al., "Biology and molecular biology of human immunodeficiency virus," <i>Pediatr. Infect. Dis. J.</i> , 11: 390-400, 1992.	
	C2	Burns et al., "The Imidazoquinolines, Imiquimod and R-848, Induce Functional, but Not Phenotypic, Maturation of Human Epidermal Langerhans' Cells," <i>Clinical Immunology</i> , 94(1): 13-23, 2000.	
	C3	Deonarain, "Ligand-targeted receptor-mediated vectors for gene delivery," <i>Exp. Opin. Ther. Patents</i> , 8(1): 53-69, 1998.	
	C4	Dockrell et al., "Imiquimod and resiquimod as novel immunomodulators," <i>Journal of Antimicrobial Chemotherapy</i> , 48: 751-755, 2001.	

Examiner
SignatureDate
Considered

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/507,928
				Filing Date	March 19, 2003
				First Named Inventor	Ralph P. Braun
				Art Unit	1633
				Examiner Name	Not Yet Assigned
Sheet	2	of	2	Attorney Docket Number	HO-P03173US0

C5	Eck et al., "Gene-Based Therapy," In: <i>Goodman & Goodman's The Pharmacological Basis of Therapeutics</i> , 9th Ed., McGraw-Hill, pp. 77-101, 1996.	
C6	Gorecki, "Prospects and problems of gene therapy: an update," <i>Expert Opin. Emerging Drugs</i> , 6(2): 187-198, 2001.	
C7	Greene, "The Molecular Biology of Human Immunodeficiency Virus Type 1 Infection," <i>The New England Journal of Medicine</i> , 324(5): 308-317, 1991.	
C8	Harrison et al., "Reduction of recurrent HSV disease using imiquimod alone or combined with a glycoprotein vaccine," <i>Vaccine</i> , 19: 1820-1826, 2001.	
C9	Hemmi et al., "Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway," <i>Nature Immunology</i> , 3(2): 196-200, 2002.	
C10	Johnson, "Molecular Adjuvants and Immunomodulators: New Approaches to Immunization," <i>Clinical Microbiology Reviews</i> , 7(3): 277-289, 1994.	
C11	Liszewicz et al., "Therapeutic vaccination for future management of HIV/AIDS," <i>Vaccine</i> , 21:620-623, 2003.	
C12	Skalka, "Introduction," <i>Advances in Virus Research</i> , Institute for Cancer Research, Fox Chase Cancer Center, Philadelphia, Pennsylvania, 52: 271-273, 1999.	
C13	Spruance et al., "Application of a Topical Immune Response Modifier, Resiquimod Gel, to Modify the Recurrence Rate of Recurrent Genital Herpes: A Pilot Study," <i>The Journal of Infectious Diseases</i> , 184: 196-200, 2001.	
C14	Tang et al., "Genetic immunization is a simple method for eliciting an immune response," <i>Nature</i> , 356: 152-154, 1992.	
C15	Tomai et al., "Immunomodulating and antiviral activities of the imidazoquinoline S-28463," <i>Antiviral Research</i> , 28: 253-264, 1995.	
C16	Ulmer et al., "Heterologous Protection Against Influenza by Infection of DNA Encoding a Viral Protein," <i>Science</i> , 259: 1745-1749, 1993.	
C17	Verma et al., "Gene therapy - promises, problems and prospects," <i>Nature</i> , 389: 239-242, 1997.	
C18	Wang et al., "Gene inoculation generates immune responses against human immunodeficiency virus type 1," <i>Proc. Natl. Acad. Sci. USA</i> , 90: 4156-4160, 1993.	
C19	Yao et al., "Virus-like particle and DNA-based candidate AIDS vaccines," <i>Vaccine</i> , 21: 638-643, 2003.	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--



Certificate of Express Mailing Under 37 CFR 1.10

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail, Airbill No. EV 678185564 US in an envelope addressed to:

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

on July 26, 2006
Date


Signature

Julie Erwin

Typed or printed name of person signing Certificate

Registration Number, if applicable

(713) 651-5187

Telephone Number

Note: Each paper must have its own certificate of mailing, or this certificate must identify each submitted paper.

IDS (Citation) by Applicant (2 pages)
Information Disclosure Statement (2 pages)
Transmittal (1 page)
22 References